drugset / Trial / NCT06576401
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects
NaSingle-groupOpen-labelTreatment
Summary
In this study, a single dose of \[14C\] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral \[14C\] HDM002.
Timeline
- Start
- 2024-08-27
- Primary completion
- 2024-10
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HDM1002 | Unknown | — | Oral |
Indications
No indication recorded.